NPC Clinical Trials

1 recruiting

Frequently Asked Questions

Common questions about NPC clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 26 trials

Recruiting
Phase 2

Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Cancinoma (NPC)
Sun Yat-sen University243 enrolled4 locationsNCT07362979
Recruiting
Phase 3

Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC

Nasopharyngeal Carcinoma (NPC)
First Affiliated Hospital of Guangxi Medical University266 enrolled1 locationNCT07459296
Recruiting
Phase 3

Sapylin Versus Dexamethasone Inhalation for CCRT-Induced Oral Mucositis in Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma (NPC)
Affiliated Hospital of Guangdong Medical University180 enrolled1 locationNCT07327216
Recruiting
Phase 2

Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial

Nasopharyngeal Carcinoma (NPC)First-line Treatment Failure Nasopharyngeal Carcinoma
Sun Yat-sen University41 enrolled1 locationNCT07101744
Recruiting
Phase 3

Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial

Nasopharyngeal Carcinoma (NPC)
Man Hu300 enrolled1 locationNCT07340515
Recruiting
Phase 3

Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy

Nasopharyngeal Carcinoma (NPC)
Ming-Yuan Chen456 enrolled12 locationsNCT07328841
Recruiting
Phase 3

Individualized Neck Cervical Irradiation Prophylaxis Trial of NPC

Nasopharyngeal Carcinoma (NPC)
Fudan University462 enrolled6 locationsNCT07303023
Recruiting
Phase 3

Phase III Non-Inferiority Trial: Reduced-Target vs. Full-Target IMRT After Chemo in Immunotherapy-Treated Metastatic Nasopharyngeal Cancer

Nasopharyngeal Carcinoma (NPC)
Ming-Yuan Chen166 enrolled1 locationNCT07188584
Recruiting
Phase 2

Induction High-Low Dose Radiotherapy Plus Anti-PD-1 Followed by Definitive Radiotherapy in Recurrent Nasopharyngeal Carcinoma (Single-Arm Phase II)

Nasopharyngeal Carcinoma (NPC)Recurrent Nasopharyngeal Neoplasms
Jiangxi Provincial Cancer Hospital23 enrolled1 locationNCT07277764
Recruiting
Phase 2

A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy

Nasopharyngeal Carcinoma (NPC)
Shanghai Henlius Biotech70 enrolled15 locationsNCT06839066
Recruiting
Phase 3

Reduced-dose vs Standard-dose Irradiation for Low-risk Clinical Target Volume in Nasopharyngeal Carcinoma.

Nasopharyngeal Cancinoma (NPC)
Sun Yat-sen University550 enrolled1 locationNCT07201337
Recruiting
Phase 2

LDRT and Chemoimmunotherapy in NPC With Liver Metastasis

Nasopharyngeal Cancinoma (NPC)
Hunan Cancer Hospital26 enrolled7 locationsNCT06788002
Recruiting
Phase 1Phase 2

SSTR2 Imaging With [68Ga]Ga-DOTA-TOC PET/CT in NPC

Nasopharyngeal Carcinoma (NPC)
University Medical Center Groningen10 enrolled1 locationNCT06982300
Recruiting
Phase 2

Effect of Nutritional Management on Patients With Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma (NPC)
Jiangxi Provincial Cancer Hospital109 enrolled1 locationNCT07085988
Recruiting

An International Study on Pediatric Patients With Rare Tumors.

MesotheliomaThyroid CarcinomaPleuropulmonary Blastoma+11 more
Azienda Ospedaliera di Padova6,250 enrolled1 locationNCT07072143
Recruiting
Phase 2

Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Radiotherapy

Nasopharyngeal Cancinoma (NPC)
Fudan University76 enrolled1 locationNCT07067268
Recruiting
Phase 3

QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.

Nasopharyngeal CancerNasopharyngeal Cancinoma (NPC)
Sun Yat-Sen University Cancer Center580 enrolled19 locationsNCT06749899
Recruiting
Phase 1Phase 2

EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma

Nasopharyngeal Cancinoma (NPC)Metastatic Nasopharyngeal CarcinomaRecurrent Nasopharynx Carcinoma
Sun Yat-Sen University Cancer Center148 enrolled1 locationNCT06802835
Recruiting
Phase 3

Toripalimab Vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma (NPC)
Sun Yat-sen University466 enrolled1 locationNCT06712888
Recruiting
Not Applicable

Comparison and Strategy Optimization of Plasma EBV DNA and P85-Ab with VCA/EBNA1-IgA for Screening Nasopharyngeal Carcinoma in High-risk Areas

ScreeningNasopharyngeal Carcinoma (NPC)Epstein Barr Virus
Ming-Yuan Chen68,649 enrolled1 locationNCT06870435